A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance)

PURPOSE: Preclinical and clinical data have shown promise in using antiangiogenic agents to treat malignant pleural mesothelioma (MPM). We conducted this phase II study to evaluate the efficacy and toxicity of single‐agent pazopanib in patients with MPM. MATERIALS AND METHODS: Patients with MPM who...

Full description

Saved in:
Bibliographic Details
Published in:Oncologist
Main Authors: Parikh, Kaushal, Mandrekar, Sumithra J., Allen‐Ziegler, Katie, Esplin, Brandt, Tan, Angelina D., Marchello, Benjamin, Adjei, Alex A., Molina, Julian R.
Format: Artigo
Language:Inglês
Published: John Wiley & Sons, Inc. 2019
Subjects:
Lung Cancer
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7288653/
https://ncbi.nlm.nih.gov/pubmed/31872928
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0574
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items